JP2010502706A - キナーゼ阻害活性を有するフェネチルアミド誘導体 - Google Patents

キナーゼ阻害活性を有するフェネチルアミド誘導体 Download PDF

Info

Publication number
JP2010502706A
JP2010502706A JP2009527385A JP2009527385A JP2010502706A JP 2010502706 A JP2010502706 A JP 2010502706A JP 2009527385 A JP2009527385 A JP 2009527385A JP 2009527385 A JP2009527385 A JP 2009527385A JP 2010502706 A JP2010502706 A JP 2010502706A
Authority
JP
Japan
Prior art keywords
ring
aliphatic
optionally substituted
alkyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009527385A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502706A5 (enExample
Inventor
アレクサンドラ イー． グールド，
ポール ディー． グリーンスパン，
トリシア ジェイ． ボス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2010502706A publication Critical patent/JP2010502706A/ja
Publication of JP2010502706A5 publication Critical patent/JP2010502706A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
JP2009527385A 2006-09-07 2007-09-05 キナーゼ阻害活性を有するフェネチルアミド誘導体 Withdrawn JP2010502706A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84293106P 2006-09-07 2006-09-07
PCT/US2007/019325 WO2008030448A1 (en) 2006-09-07 2007-09-05 Phenethylamide derivatives with kinase inhibitory activity

Publications (2)

Publication Number Publication Date
JP2010502706A true JP2010502706A (ja) 2010-01-28
JP2010502706A5 JP2010502706A5 (enExample) 2011-10-20

Family

ID=39015981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527385A Withdrawn JP2010502706A (ja) 2006-09-07 2007-09-05 キナーゼ阻害活性を有するフェネチルアミド誘導体

Country Status (4)

Country Link
US (1) US20080064729A1 (enExample)
EP (1) EP2061761A1 (enExample)
JP (1) JP2010502706A (enExample)
WO (1) WO2008030448A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015506353A (ja) * 2011-12-31 2015-03-02 ベイジーン リミテッド Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
JP2016196446A (ja) * 2016-01-04 2016-11-24 ベイジーン リミテッド Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2431466T3 (es) * 2006-06-30 2013-11-26 Sunesis Pharmaceuticals, Inc. Inhibidores de piridinonil pdk1
ES2531396T3 (es) 2008-01-23 2015-03-13 Bristol Myers Squibb Co Proceso para preparar compuestos de piridinona
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
UA105005C2 (uk) * 2008-06-16 2014-04-10 Юніверсіті Оф Теннессі Рісерч Фаундейшн Сполуки для лікування раку
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
CA2791738C (en) 2010-03-01 2020-06-09 Gtx, Inc. Aryl imidazolyl compounds for the treatment of cancer
CN102010367B (zh) * 2010-12-17 2012-10-10 山东金城医药化工股份有限公司 一种高纯度4-氯-2-吡啶甲酸甲酯盐酸盐的制备工艺
CN102532123B (zh) * 2010-12-29 2016-03-09 中国医学科学院药物研究所 噻唑-5-甲酰胺化合物、及其制法和药物组合物与用途
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
AU2016248376B2 (en) 2015-04-15 2020-10-08 Beone Medicines I Gmbh Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
CN105218436B (zh) * 2015-10-21 2019-02-05 济南诚汇双达化工有限公司 一种制备4-氯-2-吡啶甲酸甲酯的方法
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
CA3086765A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN110407824B (zh) * 2019-08-08 2021-07-02 安徽医科大学 芳基甲酰胺类化合物及其制备方法、药物组合物及用途
WO2025019600A2 (en) * 2023-07-18 2025-01-23 The General Hospital Corporation Modulators of neurodegeneration

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE730884A (enExample) * 1968-04-01
US4478853A (en) * 1982-05-17 1984-10-23 S. C. Johnson & Son, Inc. Skin conditioning composition
US4500710A (en) * 1983-06-16 1985-02-19 Mitsubishi Chemical Industries, Limited Quinophthalone dyes for cellulose-containing fibers
GB9107043D0 (en) * 1991-04-04 1991-05-22 Pfizer Ltd Therapeutic agents
DE4220983A1 (de) * 1992-06-26 1994-01-05 Bayer Ag Imidazolyl-substituierte Phenylpropion- und -zimtsäurederivate
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
DE50006615D1 (de) * 1999-08-07 2004-07-01 Boehringer Ingelheim Pharma Carbonsäureamide, deren herstellung und deren verwendung als arzneimittel
US6982348B2 (en) * 2001-01-26 2006-01-03 Takeda Pharmaceutical Company Limited Aminoethanol derivatives
US6831193B2 (en) * 2001-05-18 2004-12-14 Abbott Laboratories Trisubstituted-N-[(1S)-1,2,3,4-Tetrahydro-1-naphthalenyl]benzamides which inhibit P2X3 and P2X2/3 containing receptors
EP1593667A4 (en) * 2003-02-12 2009-03-04 Takeda Pharmaceutical Amine derivative
FR2856065B1 (fr) * 2003-06-13 2005-08-19 Servier Lab Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
PL1663978T3 (pl) * 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
JP2005263787A (ja) * 2004-02-17 2005-09-29 Ishihara Sangyo Kaisha Ltd アミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
AU2006204724A1 (en) * 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015506353A (ja) * 2011-12-31 2015-03-02 ベイジーン リミテッド Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
JP2016196446A (ja) * 2016-01-04 2016-11-24 ベイジーン リミテッド Ｒａｆキナーゼ阻害剤としての縮合三環式化合物
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
US11534431B2 (en) 2016-07-05 2022-12-27 Beigene Switzerland Gmbh Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer

Also Published As

Publication number Publication date
WO2008030448A1 (en) 2008-03-13
US20080064729A1 (en) 2008-03-13
EP2061761A1 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
US20080064729A1 (en) Phenethylamide derivatives with kinase inhibitory activity
JP6741825B2 (ja) Ｄｎａ−ｐｋ阻害剤
RU2505538C2 (ru) Новые пиридиноны и пиридазиноны
US10280150B2 (en) Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
JP2009519908A (ja) キナーゼ阻害活性を有する二環式化合物
JP2021526551A (ja) キナーゼ阻害剤としてのヘテロ環式化合物、ヘテロ環式化合物を含む組成物、及びそれらを使用する方法
JP2008527007A (ja) Ｒａｆ−キナーゼ阻害活性を有するシンナミドおよびヒドロシンナミド誘導体
US20120015942A1 (en) Substituted hydroxamic acids and uses thereof
JP2010513519A (ja) キナーゼインヒビター活性を有するある種のピラゾリン誘導体
TW200526635A (en) Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
KR20160122736A (ko) 헤테로아릴 및 이의 용도
US10323018B2 (en) Quinazoline and quinoline compounds and uses thereof
TWI891753B (zh) 醯胺類化合物及其用途
JP2014527981A (ja) アミド化合物、組成物およびその用途
US12053459B2 (en) CDK2 inhibitors and methods of using the same
CA3167785A1 (en) Heterocyclic compounds for modulating nr2f6
JP7856666B2 (ja) 三環式化合物およびその使用
US20240317686A1 (en) RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
TW202110801A (zh) 新型醯胺類化合物及其用途
CN112047877A (zh) 新型酰胺类化合物及其用途
HK40105207A (en) Amide compounds and uses thereof
HK40104416A (en) Amide compounds and uses thereof
HK40109089A (en) Amide compounds and uses thereof
HK40082804B (en) Amide compounds and uses thereof
CN103958473B (zh) 酰胺类化合物、组合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100817

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20111227

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20120110